health news today obesity drugs glp-1 The revolution: What UAB researchers are discovering about how these work Professor Receives Grant to Study

Oral semaglutide (Rybelsus) is taken once daily in a fasting state

The approval of orforglipron signals both a shift toward more accessible obesity treatments and a test case for the FDAs new accelerated review pathway

[DOI] [PubMed] [Google Scholar] 186.Tibaduiza E.C., Chen C., Beinborn M

Comparing it to someone else is misleading and often leads to inappropriate dose adjustments

Rosenstock J, Raccah D, Koranyi L, Maffei L, Boka G, Miossec P, et al

Although not directly related to inflammation due to a physiologic change in the microenvironment, GLP-1RAs have the potential to replace current standard of care treatment for IIH and can ultimately contribute to improved patient outcomes in the field of neuro-ophthalmology